The cornerstone of adjuvant treatment for hormone receptor-positive early breast cancer is endocrine therapy, tailored according to the disease stage, tumour’s biological characteristics, patients’ comorbidities, preferences and age [40–42]. Here, NR4A1 is linked to breast cancer.